ArticleDermatology (Basel, Switzerland)2026
15-Year Experience of Patch Testing during Pregnancy: Retrospective Case-Control Study from a Tertiary Israeli Center.
Article in Dermatology (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Although patch testing (PT) is not contraindicated during pregnancy, most dermatologists defer testing due to lack of data and possibility that immunological changes might influence outcomes. In our center, we routinely perform PT during pregnancy as it is not known to be teratogenic and may lead to significant improvements in quality of life. This study aimed to assess whether pregnancy alters the outcome of PT.
methodsRetrospective, single-center case-control study was conducted at a tertiary Israeli dermatology clinic (2009-2023). Women who gave birth within 40 weeks of PT were identified, and for each, three age-, year-, and atopic dermatitis-matched controls were selected.
resultsOf 3,351 women tested, 54 (1.6%) were pregnant at the time of PT. Most were tested during the first trimester (63%). No significant differences were found in the frequency of positive patch test reactions between pregnant women and matched controls. The most common allergens in pregnant patients were nickel sulfate (61.1%), 2-hydroxyethyl methacrylate (13.64%), and fragrance mix II (5.5%).
conclusionPregnancy does not appear to affect patch test outcomes in early and mid-gestation. Due to limited third-trimester representation, further studies are needed to determine whether reactivity remains consistent throughout all stages of pregnancy. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.